Physician profile
Christopher Gross
NPI 1902034283
$394,142.72
in general payments reported to CMS, 2019-2025
46 companies · $69K in 2025
The $69K reported for 2025 was more than what 93% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,688 · 2020: $11K · 2021: $13K · 2022: $96K · 2023: $118K · 2024: $83K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $214K · Travel and Lodging: $33K · Food and Beverage: $11K · Royalty Or License: $6,377 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,600 · Grant: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $214,034.36 |
| Travel and Lodging | $33,290.95 |
| Food and Beverage | $10,891.86 |
| Royalty Or License | $6,377.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,600.00 |
| Grant | $546.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $157,599.71 | 2019-2025 | Portfolio, Additive Orthopedics, Apex 3d |
| Vilex LLC | $50,666.36 | 2023-2025 | Next Gen Ankle, Dynex |
| Stryker Corporation | $37,273.12 | 2019-2025 | Infinity, Invision, Easyfuse |
| Acumed LLC | $33,452.50 | 2020-2025 | Acumed, Innate Implant, Osteomed |
| Medshape, INC. | $29,014.16 | 2020-2025 | Dynanail, Dynanail Mini, Dynanail Helix, Washer, 15 Mm |
| Trilliant Surgical LLC. | $19,533.70 | 2022-2024 | Arsenal Sinus Support Plate, Arsenal Ankle 10 Hole 1/3 Tubular Plate |
| Fusion Orthopedics USA, LLC | $15,919.45 | 2023-2025 | Lapilock and Chamfered Screws, Lapilock |
| Flower Orthopedics Coporation | $11,661.37 | 2022-2025 | |
| Oxford Performance Materials, INC. | $5,311.28 | 2024-2025 | |
| Bioventus LLC | $3,658.50 | 2019-2024 | Exogen Ultrasound Bone Healing System |
| Wright Medical Technology, INC. | $3,370.01 | 2019-2020 | |
| Forma Medical | $2,766.71 | 2025 | Optimalmtp |
| Peerless Surgical INC. | $2,622.27 | 2019-2025 | |
| Arthrex, INC. | $2,276.92 | 2020-2025 | Arthrex |
| Ossio INC | $2,145.96 | 2023-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Solutions INC | $1,861.72 | 2022-2025 | |
| Synthes USA Products LLC | $1,815.00 | 2024 | |
| Novastep INC. | $1,800.00 | 2023 | Peca Bunion Correction System |
| Encore Medical, Lp | $1,484.14 | 2022 | |
| Orthofix Medical, INC. | $1,288.06 | 2020-2025 | Truelok, Ankle Hindfoot Nailing System |
| Medline Industries Lp | $1,145.41 | 2021-2025 | |
| Smith+Nephew, INC. | $1,072.09 | 2019-2025 | Salto Talaris Total Ankle Prosthesis, Evos, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Kerecis Limited | $1,021.61 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| International Life Sciences | $812.73 | 2023-2024 | Flexband |
| Alafair Biosciences, INC. | $744.17 | 2022-2025 | Versawrap |
| Integra Lifesciences Corporation | $560.07 | 2019-2020 | |
| Treace Medical Concepts, INC. | $512.94 | 2021-2024 | |
| Arteriocyte Medical Systems, INC. | $446.04 | 2019-2025 | Magellan |
| Depuy Synthes Sales INC. | $397.81 | 2019-2023 | Na |
| Zimmer Biomet Holdings, INC. | $384.75 | 2020-2024 | |
| Exactech, INC. | $355.53 | 2019-2023 | |
| Bone Support INC. | $279.01 | 2025 | Ceramentbone Void Filler, Cerament G |
| Sanara Medtech INC. | $146.26 | 2024 | Celleraterx |
| Biotissue Holdings INC. | $144.87 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $121.06 | 2023 | Seglentis |
| Restor3d, INC. | $97.05 | 2023 | |
| Next Science LLC | $82.50 | 2022 | |
| Djo, LLC | $67.19 | 2023 | Donjoy, Aircast |
| Additive Orthopaedics, LLC | $53.02 | 2019 | |
| Glw, INC | $51.32 | 2023 | Apollo Ankle |
| Medtronic, INC. | $47.82 | 2022-2023 | Intellis Adaptivestim |
| Kuros Biosciences USA, INC | $18.82 | 2023 | |
| Metric Medical Devices, INC. | $18.10 | 2022-2023 | Super Staple, Super Scaffold |
| Fusion Orthopedics, LLC. | $17.84 | 2024 | Lapilock and Chamfered Screws |
| Innovation Technologies INC | $14.75 | 2025 | Irrisept |
| Dynasplint Systems INC. | $9.02 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,793.36 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$176,217.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.